Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11542528 Transposition-based therapies

Overview Structured Data Issues Contributors Activity

Is a

Current Assignee

Saliogen Therapeutics, Inc.

Date Filed

February 11, 2022

Date of Patent

January 3, 2023

Patent Applicant

Saliogen Therapeutics, Inc.

Patent Application Number

17669939

Patent Citations

US Patent 10415022 Trichoplusia ni piggyBac transposases with reduced integration activity

US Patent 10435696 DNA vectors, transposons and transposases for eukaryotic genome modification

US Patent 10533190 Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

US Patent 10550407 Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

US Patent 10793878 Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

US Patent 10900054 Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

US Patent 10927384 DNA vectors, transposons and transposases for eukaryotic genome modification

US Patent 11060086 Transposition of nucleic acids into eukaryotic genomes with a transposase from heliothis

US Patent 11060098 Integration of nucleic acid constructs into eukaryotic cells with a transposase from oryzias

US Patent 11162102 Modifications of mammalian cells using artificial micro-RNA to alter their properties and the compositions of their products

•••

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Primary Examiner

Jennifer Dunston

CPC Code

Find more entities like US Patent 11542528 Transposition-based therapies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool